Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pirtobrutinib

FDA-approved product (tablet, oral), marketed as Jaypirca.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pirtobrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mantle cell lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pirtobrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pirtobrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

    NCT05677919 · start 2023-01-31

    Registered record
    Registry ID
    NCT05677919
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Magnetic Resonance Imaging; Pirtobrutinib; Positron Emission Tomography; Venetoclax; Echocardiography; Multigated Acquisition Scan; Biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-01-31
    Completion
    2030-09-03
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +7 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

    NCT05529069 · start 2023-01-25

    Registered record
    Registry ID
    NCT05529069
    Conditions
    Mantle Cell Lymphoma; Non Hodgkin Lymphoma; Hematologic Malignancy
    Interventions
    Pirtobrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-01-25
    Completion
    2027-04-28
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma; Non Hodgkin Lymphoma; Hematologic Malignancy
    InterventionPirtobrutinib; Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

    NCT05643235 · start 2023-01-01

    Registered record
    Registry ID
    NCT05643235
    Conditions
    Atrial Fibrillation; Supraventricular Arrhythmia; Ventricular Arrhythmias and Cardiac Arrest; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Interventions
    Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-01-01
    Completion
    2030-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Supraventricular Arrhythmia; Ventricular Arrhythmias and Cardiac Arrest; Chronic Lymphocytic Leukemia +1 more
    InterventionMedtronic LINQ-2 Insertable Cardiac Monitor (ILR)
    PhaseNot applicable
    Registry statusRecruiting

  • Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

    NCT05536349 · start 2022-12-20

    Registered record
    Registry ID
    NCT05536349
    Conditions
    Leukemia
    Interventions
    Pirtobrutinib; Obinutuzumab; Venetoclax; Valacyclovir; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-20
    Completion
    2028-04-25
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionPirtobrutinib; Obinutuzumab; Venetoclax; Valacyclovir +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

    NCT05317936 · start 2022-11-16

    Registered record
    Registry ID
    NCT05317936
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2022-11-16
    Completion
    2025-10-06
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib; Venetoclax
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    NCT05254743 · start 2022-07-22

    Registered record
    Registry ID
    NCT05254743
    Conditions
    Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-07-22
    Completion
    2028-01
    Enrolment
    737

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib; Ibrutinib
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

    NCT05283720 · start 2022-06-14

    Registered record
    Registry ID
    NCT05283720
    Conditions
    Non-Hodgkin Lymphoma
    Interventions
    Epcoritamab; Lenalidomide; Ibrutinib; Rituximab; Cyclophosphamide; Doxorubicin Hydrochloride [HCl]; Prednisone; Polatuzumab Vedotin; CC-99282
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-06-14
    Completion
    2032-11
    Enrolment
    264

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin Lymphoma
    InterventionEpcoritamab; Lenalidomide; Ibrutinib; Rituximab +5 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

    NCT05176314 · start 2022-01-11

    Registered record
    Registry ID
    NCT05176314
    Conditions
    Healthy
    Interventions
    Rosuvastatin; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-01-11
    Completion
    2022-04-20
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRosuvastatin; Pirtobrutinib
    PhasePhase 1
    Registry statusCompleted

  • Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

    NCT05024045 · start 2021-09-30

    Registered record
    Registry ID
    NCT05024045
    Conditions
    Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-cell Marginal Zone; Lymphoma, Non-Hodgkin; Multiple Myeloma; B-cell Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell
    Interventions
    LOXO-338; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-30
    Completion
    2026-04-01
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-cell Marginal Zone; Lymphoma, Non-Hodgkin; Multiple Myeloma +3 more
    InterventionLOXO-338; Pirtobrutinib
    PhasePhase 1
    Registry statusCompleted

  • A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

    NCT06258174 · start 2021-09-28

    Registered record
    Registry ID
    NCT06258174
    Conditions
    Healthy
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-28
    Completion
    2021-12-22
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPirtobrutinib
    PhasePhase 1
    Registry statusCompleted

  • A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    NCT04965493 · start 2021-09-20

    Registered record
    Registry ID
    NCT04965493
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Venetoclax; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-20
    Completion
    2027-10
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib; Venetoclax; Rituximab
    PhasePhase 3
    Registry statusActive not recruiting

  • Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    NCT04666038 · start 2021-03-09

    Registered record
    Registry ID
    NCT04666038
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Idelalisib; Bendamustine; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-03-09
    Completion
    2027-05
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib; Idelalisib; Bendamustine; Rituximab
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

    NCT06180980 · start 2021-01-04

    Registered record
    Registry ID
    NCT06180980
    Conditions
    Healthy
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-04
    Completion
    2021-03-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPirtobrutinib
    PhasePhase 1
    Registry statusCompleted

  • Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

    NCT06190691 · start 2020-12-18

    Registered record
    Registry ID
    NCT06190691
    Conditions
    Healthy; Hepatic Insufficiency
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-18
    Completion
    2021-12-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Hepatic Insufficiency
    InterventionPirtobrutinib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

    NCT06215521 · start 2020-12-15

    Registered record
    Registry ID
    NCT06215521
    Conditions
    Healthy
    Interventions
    Pirtobrutinib; Placebo; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-15
    Completion
    2021-03-31
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPirtobrutinib; Placebo; Moxifloxacin
    PhasePhase 1
    Registry statusCompleted